Business · 22/01/2018Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for PERCEVAL Sutureless Heart Valve Patent Extension
Summary
The US Food and Drug Administration has published a notice determining the regulatory review period for the extension of a patent for the PERCEVAL Sutureless Heart Valve, following a submission to the US Patent and Trademark Office.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →